
Allovir Inc (KLRS) Stock Forecast & Price Target
Allovir Inc (KLRS) Analyst Ratings
Bulls say
Kalaris Therapeutics is positioned for success with its lead candidate TH103 which has already demonstrated promising preliminary data with significant improvements in BCVA and CST and a high level of patients remaining rescue-free for up to six months. Additionally, with the completion of enhancements to its manufacturing process and a strong management team, the company has addressed potential safety concerns and is well-positioned for success in the crowded market for wet AMD therapeutics.
Bears say
Kalaris Therapeutics is heavily reliant on the success of a single asset, TH103, which is currently in Phase 1b/2 clinical trials and may face challenges in effectively commercializing its products. There is also significant risk from market competition and potential delay in clinical development, regulatory approvals, or commercialization timelines. Additionally, the company has incurred significant losses and will require substantial funds to finance its pipeline, making its stock price vulnerable to market fluctuations and overall economic conditions.
This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.
Allovir Inc (KLRS) Analyst Forecast & Price Prediction
Start investing in Allovir Inc (KLRS)
Order type
Buy in
Order amount
Est. shares
0 shares